iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.


Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the… (More)
DOI: 10.1016/S1470-2045(17)30074-8